Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction of food intake at 10 mg/kg, po administered daily for 3 days relative to dirlotapide
Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction in body weight at 10 mg/kg, po administered daily for 3 days relative to dirlotapide
Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction of triglyceride accumulation in liver at 10 mg/kg, po administered daily for 3 days relative to dirlotapide
Antiobesity activity in po dosed high fat diet-induced obese Sprague-Dawley rat assessed as reduction of reduction of triglyceride accumulation in liver administered daily for 3 days
Inhibition of MTP in human HepG2 cells assessed as unbound drug level causing inhibition of apoB secretion after 40 hrs by ELISA relative to dirlotapide
Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction of triglyceride accumulation in liver at 30 mg/kg, po qd for 7 days relative to control
Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction of triglyceride accumulation in liver at 10 mg/kg, po qd for 7 days relative to control
Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction of triglyceride accumulation in liver at 3 mg/kg, po qd for 7 days relative to control
Antiobesity activity in high fat diet-induced obese Sprague-Dawley rat assessed as reduction of body weight at 10 mg/kg, po qd for 7 days relative to control